

No	First Name	Last Name	Country	Title of Abstract
10000	Ming-lung	Yu	Taiwan	Real-World Effectiveness and Safety of 8-Week Glecaprevir/pibrentasvir for Pwld and Hiv Patients from Taiwan Nationwide HCV Registry
10001	Hiraoka	Atsushi	Japan	Interaction Between Simplified Balad Score and Treatment Efficacy of Immune Checkpoint Inhibitor Regimens in Unresectable Hepatocellular Carcinoma
10002	Anh Ngoc	Doi	Viet Nam	False Positivity of Pivka-Ii in Non-HCC Liver Disease:a Real-World Clinical Analysis from Vietnam
10003	Fujimasa	Tada	Japan	Clinical Significance and Determinants of Hemorrhagic Events in Unresectable Hepatocellular Carcinoma Under Atezolizumab Plus Bevacizumab Therapy
10004	Eihmile Kreistein N	Salgado	Philippines	The Prevalence of Nonalcoholic Fatty Liver Disease (nafld) Using Sonographic Qualitative Assessment Among Filipino Patients with Metabolic Syndrome in a Tertiary Hospital in Iloilo City: a Pilot Study
10005	Yukihiro	Watanabe	Japan	Burnt-Out MASLD Predicts Outcomes After Curative Resection for Hepatocellular Carcinoma
10006	Ying Nan	Tsai	Taiwan	Comparative Effectiveness and Safety of Atezolizumab-Bevacizumab and Durvalumab-Tremelimumab As First-Line Systemic Therapy for Hepatocellular Carcinoma: a Real-World Study
10007	Hana	Park	Korea	Differential Cancer Risks and Noninvasive Predictors in Masld, Metald, and Ald: a Longitudinal Analysis
10008	Hideko	Ohama	Japan	Extended Five-Year Outcomes of First-Line Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma: a Multicenter Real-World Study
10009	Atsushi	Ono	Japan	Metabolic Dysfunction-Associated Steatotic Liver Disease Increases the Risk of Hepatocellular Carcinoma After Sustained Virologic Response in Chronic Hepatitis C
10010	Eisuke	Murakami	Japan	Association of the Elf Score with Liver-Related Complications and Cardiovascular Events in Metabolic Dysfunction-Associated Steatohepatitis
10011	Takanori	Suzuki	Japan	Phosphorylated Hepatitis B Core Antigen Levels Predicts Progression to Chronic Hepatitis in Hbeag-Negative Gray Zone Patients with Chronic HBV Infection
10012	Ekram	Hasanin	Libya	Novel Trends in Liver Transplantation for MASLD and Ald: Emerging Epidemiology, Allocation& Post-Transplant Challenges
10013	Vu Van	Khien	Viet Nam	Efficacy and Safety of Drug-Eluting Beads Trans-Arterial Chemoembolization for Hepatocellular Carcinoma in Vietnam
10015	Vu Van	Khien	Viet Nam	Yttrium-90 Transarterial Radioembolization for Hepatocellular Carcinoma: Summary of 10 Years from Two Centers in Vietnam
10016	Won-mook	Choi	Korea	Long-Term Persistence of the Parabolic Association Between Baseline HBV DNA and Hepatocellular Carcinoma Risk After Antiviral Therapy
10017	Tomohide	Kurahashi	Japan	Early Weight Response Identifies a High-Risk Phenotype in MASLD Patients Treated with Tirzepatide
10018	Tomoko	Tadokoro	Japan	Recurrent Intraoperative Bradycardia During Radiofrequency Ablation for Hepatocellular Carcinoma
10019	Arjun	Maria	India	Development and Validation of an Ai Driven Convolutional Neural Network for Automated Stool Colour Classification to Facilitate Early Diagnosis of Biliary Atresia
10020	Arjun	Maria	India	Impact of Continuous Renal Replacement Therapy on Survival and Ammonia Clearance in Hepatitis a Virus Associated Pediatric Acute Liver Failure with Advanced Hepatic Encephalopathy: a Two-Centre Retrospective Cohort Analysis
10021	Arjun	Maria	India	Spectrum and Clinical Impact of Liver Involvement in Children Hospitalized with Respiratory Viral Infections
10022	Khiem K	Pham	Viet Nam	Primary Biliary Cholangitis in Vietnam: Heterogeneous Biochemical Patterns and a High Proportion of Ama-Negative Cases
10023	Sanae	Kimura	Japan	Emergence of the HBV Rtl269i Mutation and Its Contribution to Multidrug Resistance During Entecavir and Tenofovir Therapy
10024	Mi Na	Kim	Korea	Effect of Diabetes on the Risk of Fibrosis Progression in Patients with Chronic Hepatitis B
10025	Mi Na	Kim	Korea	The Impact of Alcohol Consumption on the Risk of Hepatocellular Carcinoma Across Different Age Groups: a Nationwide Cohort Study
10026	Shiho	Miyase	Japan	Impact of Liver Steatosis on Hepatocarcinogenesis in Chronic Hepatitis B Patients Receiving Nucleos(t)ide Analog Therapy
10027	Arjun	Maria	India	Non-Destructive Ebv-Associated Ptld Presenting with Gastrointestinal Bleeding in a Post-Liver Transplant Child: Diagnostic and Therapeutic Challenges
10028	Bibek	Thapa	Nepal	Community-Led Harm Reduction Pathways to End Hepatitis C Elimination Barriers Among People Who Use Drugs in Nepal
10029	Chien-hung	Lu	Taiwan	Validation of the Up7-Albi Score for Prognostication in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab
10030	Jie	Yu	China	Betaine Homocysteine Methyltransferase Attenuates Metabolic Dysfunction-Associated Steatohepatitis by Inhibiting Notch4-Hes1 Pathway
10032	Tuan Anh	Pham	Japan	Ccdc80 As a Novel Marker and Therapeutic Target in Liver Fibrosis: a Single-Cell RNA Sequencing Study
10033	Babylyn	Oab	Philippines	Fever Without Focus: an Atypical Presentation of Hypervirulent Klebsiella Pneumoniae Liver Abscess in Newly Diagnosed Diabetes Mellitus
10035	Taketo	Fukuoka	Japan	A Novel Abca1 Mutation in Shrsp5/dmcr Rats Promotes MASH via Hepatic Free Cholesterol Overload and Nlrp3 Inflammasome Activation
10036	Chaiyaboot	Ariyachet	Thailand	Znf469 Coordinates a Metabolic Program for Collagen Synthesis by Regulating Amino Acid Transport and Biosynthetic Enzymes
10038	Takahisa	Fujikawa	Japan	Multidisciplinary Treatment Combining Systemic Biologic Therapy and Minimally Invasive Hepatectomy for Borderline-Resectable Hepatocellular Carcinoma: an Analysis of 10 Consecutive Cases
10039	Hiroki	Inada	Japan	Therapeutic Activation of Wnt/β-Catenin Signaling Accelerates Resolution of Hepatic Steatosis in MASLD Models
10040	Monirujjaman	Biswas	India	Exploratory and Predictive Analytics of Covid-19's Impact on Liver Cancer Outcomes
10041	Monirujjaman	Biswas	India	Unveiling Glucose-Independent and Reversible Metabolic Pathways in Metformin's Anti-Proliferative Action on Liver Cancer Cells
10042	Monirujjaman	Biswas	India	Efficient Deep Learning Framework for Nucleus Segmentation from the Histopathological Images in Liver Cancer
10043	Monirujjaman	Biswas	India	Diagnostic Approach to Histomorphological and Immunohistochemical Spectrum of Metastatic Liver Lesions
10044	Natsumi	Tsukano	Japan	Steatotic Liver Disease During Steroid Therapy in Patients with Autoimmune Hepatitis and Its Associated Factors
10045	Shoma	Yoneda	Japan	Diagnostic Performance of Serum Methylated Somatostatin Liquid Biopsy for Hepatocellular Carcinoma: Comparison with Methylated <i>hoxa1</i> and <i>sept9</i>
10046	Kaede	Fujita	Japan	Imeglimin in MASLD with Type 2 Diabetes: a Pilot Study on Hepatic and Metabolic Improvements
10047	Yuki	Kunimune	Japan	Quantitative Pcr-Based Measurement of Serum Methylated <i>sept9</i>, <i>hoxa1</i>, and <i>sst</i> Achieves Equivalent Diagnostic Performance to Digital Pcr for Hepatocellular Carcinoma
10048	Emi	Sometani	Japan	Proteomic Analysis of Serum Extracellular Vesicles Revealed Fibulin-3 As a Novel Predictive Biomarker for Hepatocellular Carcinoma in Patients with Chronic Hepatitis B

No	First Name	Last Name	Country	Title of Abstract
10049	Sohji	Nishina	Japan	Photothermally Modulated Liposome Enabling Efficient Release of 2-Deoxy-D-Glucose Safely Displays Vigorous Antitumor Effect Against Liver Cancer
10050	Ken	Sato	Japan	Strategic Principles for Global HCV Elimination: a Comparative Analysis of 12 Countries on Track to Meet Who Targets
10053	Demver P	Gomez	Philippines	Finite Versus Indefinite Nucleos(t)ide Analogue Therapy in Hbeag-Negative Chronic Hepatitis B: Meta-Analysis of Randomized Trials
10054	Yasuhiko	Nakao	Japan	Noninvasive Prediction of Serum Bilirubin via Scleral Color Analysis: Clinical Validation of the Lab B-Channel As a Practical Biomarker for Jaundice Screening
10055	Mohammad Khairul	Basher	Bangladesh	Comparison of Epidemiological, Biochemical, and Radiological Characteristics Between Viral and Non-Viral Etiology of Hepatocellular Carcinoma Patients
10056	Trang Diep Thanh	Le	Taiwan	Feasibility of Deep Learning-Based Automated Histopathological Scoring for Metabolic Dysfunction-Associated Steatohepatitis (MASH): a Pilot Study
10057	Sadatsugu	Sakane	Japan	Serum Fibulin-3 Predicts Hepatocellular Carcinoma Development in Patients with MASLD and Post-Daa Chronic Hepatitis C
10058	Yuta	Myojin	Japan	Childhood Obesity Promotes Liver Cancer Susceptibility Later in Life in Mouse Models
10059	Eiichi	Ogawa	Japan	Long-Term Clinical Impact of MASLD After Switching to Tenofovir Alafenamide in Patients with Chronic Hepatitis B
10061	Akinobu	Tawada	Japan	Overcoming International Disparities in Accessibility for Anticancer Drugs: an Ecological Study Using Country-Level Data
10062	Yuri	Sakamoto	Japan	A Case of Sclerosing Cholangitis That Was Difficult to Differentiate from Intrahepatic Cholangiocarcinoma
10063	Md Farhad	Hossen	Bangladesh	Perceptions and Awareness of Non-Alcoholic Fatty Liver Disease at the Community Level in Bangladesh a Cross-Sectional Study
10064	Manabu	Hayashi	Japan	Diabetes Mellitus and Prognosis in Cirrhotic Patients Experienced Overt Hepatic Encephalopathy
10065	Shih-chieh	Chien	Taiwan	Dynamic Change of New-Generation Tumor Markers in Predicting Recurrence of Hepatocellular Carcinoma Following Curative Treatment
10066	Tagayasu	Yoshiyuki	Japan	S100p Immunohistochemistry Underpins Prognostic and Molecular Stratification in Intrahepatic Cholangiocarcinoma
10067	Jacqueline	Kwa	Singapore	Raising MASLD Awareness for Early Prevention: a Public Health Education Initiative in Singapore
10068	Masafumi	Haraguchi	Japan	Impact of Extracellular Fluid Retention on Bioelectrical Impedance-Based Muscle Mass Assessment in Patients with Steatotic Liver Disease-Related Cirrhosis: a Ct-Validated Study
10069	Saima	Mushtaq	Pakistan	Viral Persistence in Hepatitis-Associated Hepatocellular Carcinoma: Translational Evidence from Liver Tissues
10070	Saima	Mushtaq	Pakistan	Targeting Hbx in HBV-Related HCC Through In-Silico and Crispr Approaches
10071	Bui Tam Chi	Nguyen	Japan	Single-Cell Transcriptomic Analysis Identifies Ccbe1 As a Novel Hsc Quiescence Marker Restored by Cytoglobin in Liver Fibrosis
10072	Minjeong	Kang	Korea	Efficacy and Safety of Adding Radiotherapy to Atezolizumab Plus Bevacizumab in Hepatocellular Carcinoma: a Systematic Review and Meta-Analysis
10073	Kathryn	Effendi	Japan	Implementation of the Anrs 0562s Hipocamp Study in Vietnam: an International Collaborative Pilot Study on the Prevention of Mother-To-Child Transmission of Hepatitis B Virus (HBV)
10074	Amjad	Khan	Pakistan	Real-World Sorafenib Adverse Events and Quality-Of-Life Trajectories in Advanced Hepatocellular Carcinoma
10075	Habib_m	Sazzad	Bangladesh	Observation of Six Months Outcome of Hepatocellular Carcinoma Patients with First Line Systemic Treatment on the Basis of Etiology
10076	Eun Seok	Kang	Korea	Development and Multicentre Validation of a Routine-Laboratory Model for Fibroscan-Defined Steatosis and Fibrosis Staging
10077	Tomoya	Hamabe	Japan	Dfna5-Dependent Secondary Necrosis Drives Macrophage Tnf/nf-κb Signaling in Chronic Liver Injury
10078	Naoki	Tanaka	Japan	Luseogliflozin Reduces Liver Tumors in Stz/hfd Mice by Suppressing <i>trib3</i> Expression
10079	Naing Naing	Mon	Singapore	A Conjugated Bile Acid-Extracellular Matrix Axis Characterises Fibrosis-Dominant MASLD and Steatosis-Fibrosis Discordance
10080	Hideaki	Miyamoto	Japan	Regimen-Specific Immune-Related Adverse Event Profiles in Patients Receiving Io-Io Combination Therapy
10081	Haruka	Taninaka	Japan	Non-Cirrhotic Portal Hypertension Caused by a Hepatic Hemangioma-Associated Intrahepatic Arterioportal Shunt Presenting with Ruptured Esophageal Varices Successfully Treated with Transarterial Embolization
10082	Shohei	Miyabe	Japan	A Case of Intrahepatic Cholangiocarcinoma Achieving Remarkable Tumor Regression via Heavy-Ion Radiotherapy Followed by Immunotherapy
10083	Hitoshi	Iwasaki	Japan	Spp1/cd44 Axis and Slc7a11-Mediated Ferroptosis Resistance in Poor Tumor Necrosis After Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma
10084	Huyen D A	Tran	Japan	Cytoglobin Deficiency Accelerated Lsec Dysfunction and Tumor Progression in Diethyl Nitrosamine Treated Cytoglobin Knock-Out Mice
10085	Yosuke	Murata	Japan	Molecular Analysis of Circulating Tumor Cells As a Translational Biomarker for Systemic Therapy in Patients with Hepatocellular Carcinoma
10086	Bunga P	Ramadhani	Indonesia	Longitudinal Assessment of Hepatitis B Virus-Specific B Cells Before and After Nucleos(t)ide Therapy in Chronic Hepatitis B Patients
10087	Ryohei	Yoshino	Japan	Inhibition of Polyamine Oxidation Modulates Hepatic Lipid Metabolism in Metabolic Dysfunction-Associated Steatotic Liver Disease
10088	Ko	Hashimoto	Japan	Early Changes in AFP and Dcp Predict Response to Nivolumab Plus Ipilimumab in Unresectable Hepatocellular Carcinoma: a Multicenter Retrospective Study
10089	Anand Krishna	Singh	India	Therapeutic Synergy of Sestrin Ampk Pathway and Sglt 2 Inhibitors from Soybean <i>glycine Max</i> in Type 2 Diabetes Associated Hepatic Dysfunction
10090	Yusuke	Seiki	Japan	The Bh3-Only Protein Noxa Promotes Hepatocyte Apoptosis and Steatosis in MASLD
10091	Takahiro	Mizuta	Japan	Impact of Hepatic Steatosis on Lsm-Based Cirrhosis Assessment and Ckd Risk Stratification in MASLD
10092	Yu	Saito	Japan	Beyond Br1/br2: Defining Surgical Indications for Borderline Resectable Hepatocellular Carcinoma Using Tumour Burden and Vascular Invasion
10093	Keisuke	Amano	Japan	Diagnostic Accuracy of a Clinically Accessible Itact-Based HCV Core Antigen Assay in a Japanese Cohort
10094	Kazuhisa	Murai	Japan	Netrin-1 Is a Novel Host Factor That Dually Inhibits HBV Entry
10095	Beta_canina	Harlyjoy	Japan	Vascular Remodelling During Liver Fibrosis Progression and Regression
10096	Xiaolei	Jin	Taiwan	Multi-Locus Hla Evolutionary Divergence and Spontaneous Hbsag Seroclearance in Chronic Hepatitis B: a Longitudinal Taiwan Biobank Study

No	First Name	Last Name	Country	Title of Abstract
10097	Yutao	Dong	Japan	A Humanized Liver Mouse Model Supporting Hepatitis a Virus Infection and Antiviral Evaluation
10099	Yohei	Shirakami	Japan	Inhibition of Indoleamine 2,3-Dioxygenase Enhances Immune Responses to a Therapeutic Vaccine for Chronic Hepatitis B
10101	Daisuke	Minowa	Japan	Exercise Improves Sarcopenia and Metabolic Dysfunction-Associated Steatohepatitis Through Activation of Skeletal Muscle Pgc-1α/sirt1 Signaling
10102	Juhun	Choi	Korea	Association Between Circadian Rhythm-Disturbing Factors and Metabolic Dysfunction-Associated Steatotic Liver Disease Among Korean Adults
10103	Kazuma	Daiku	Japan	Mcl1-Associated Immune Remodeling Mediates Resistance to Dual Immune Checkpoint Blockade in Hepatocellular Carcinoma
10104	Yang Jae	Yoo	Korea	Machine Learning Based Identification of Exosomal Mir-30a-5p As a Predictive Biomarker for Atezolizumab Plus Bevacizumab Response in Advanced Hepatocellular Carcinoma
10105	Haeun	Ryu	Korea	Association Between Magnetic Resonance Imaging-Assessed Myosteatosis and the Risk of Major Adverse Liver Outcomes
10106	Minji	Kim	Korea	Independent Association Between Serum Mac-2 Binding Protein Glycosylation Isomer and Fibroscan-Measured Liver Stiffness
10107	Keita	Shirahata	Japan	Cholangioscopy for Intrahepatic Iopn with Invasive Carcinoma: a Case Report
10108	Jia-ling	Wu	Taiwan	Risks of Hepatocellular Carcinoma and Cause-Specific Mortality in Chronic Hepatitis B with Versus Without Tyg-Wc-Defined MASLD Proxy: a Nationwide Cohort Study
10109	Anand Krishna	Singh	India	Synergistic Effects of <i>withania Somnifera</i> Alkaloid Extract and Metformin on Hepatic Ultrastructure and Biochemistry in a NAFLD Model
10110	Charupong	Saengboonmee	Thailand	The Impact of Adiposity and Leptin Signaling on Hepatocellular Carcinoma Progression and Patient Prognosis
10111	Osamu	Yoshida	Japan	Continuous Hbsag Reduction by a Nasal Administrative Therapeutic Vaccine: the Results of 7 Years Follow Up
10112	Suzuki	Takuto	Japan	Impact of Dgkα Deficiency on Liver Fibrosis in a MASLD Mouse Model
10114	Yuzuru	Sakamoto	Japan	Serum Soluble Siglec-5 Is a Prognostic Biomarker in Patients with Hepatocellular Carcinoma
10115	Yuanyuan	Chen	Hong Kong	Network-Based Metabolomic Profiling Reveals Chronic Liver Disease Progression and Identifies a Hepatocellular Carcinoma Screening Panel
10116	Minsun	Kim	Korea	Machine Learning Model for HCC Risk Prediction in MASLD Patients Using Fibroscan and Emr Data
10117	Ekram	Hasanin	Libya	Global Trends in Liver Cancer Attributable to Hepatitis B: Insights from the Globalburden of Disease 2023
10118	Chinatsu	Nishioka	Japan	Real-World Efficacy and Safety of Durvalumab Plus Tremelimumab for Unresectable Hepatocellular Carcinoma: a Multicenter Cohort Study
10120	Hironao	Okubo	Japan	Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients with Unresectable Hepatocellular Carcinoma in Early Clinical Practice: a Multicenter Analysis
10121	Atsushi	Yukimoto	Japan	Hepatocellular Carcinoma Following Svr in Patients with HCV Associated Cirrhosis and Stratification of Risk Factors: a Multicenter Study
10122	Takeshi	Chida	Japan	HBV Genomic Sequences Detected by Comprehensive Genomic Profiling Provided a Clue to the Diagnosis of Metastatic Hepatocellular Carcinoma
10123	Takuma	Kaneko	Japan	Ai Based Local Tumor Progression Prediction Following Hepatocellular Carcinoma Ablation
10124	Keisuke	Okura	Japan	Intermediate- to High-Risk Subgroups of Hepatocellular Carcinoma Characterized by Recurrence-Survival Correlation After Hepatectomy
10125	Kazuya	Okushin	Japan	Selective Testing Recommendation Considering Clinical Timelines Improve Opportunities for Hepatitis C Diagnosis
10126	Tetsuya	Hosaka	Japan	Latest Profiles of Qhbsag Among Patients Continuing Long-Term Nuc Treatment in Japan
10127	Tetsuya	Hosaka	Japan	Long-Term Changes in High-Sensitive Hbcrag Levels and Their Association with HCC in Patients Treated with Long-Term Nuc
10130	Hideto	Yuruki	Japan	Utility of the Fatty Liver Index As a Predictor of Hepatic Steatosis in Patients with Ald/metald
10131	Yu	Akazawa	Japan	Long-Term Prognostic Impact of Immune-Mediated Hepatitis in Patients Receiving Immune Checkpoint Inhibitors
10132	Hideki	Fujii	Japan	Role of Diabetes Mellitus and Platelet Count in Hepatocellular Carcinoma Development in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease
10133	Hiroki	Sugiura	Japan	Clinical Utility of a Combined HCV Antibody/antigen Assay: Comparison with a Single Antibody Assay and a Prospective Study
10134	Huong Tu	Lam	Vatican City	Multidrug-Resistant Pathogens and Treatment Non-Response in Spontaneous Bacterial Peritonitis Among Cirrhotic Patients: a Cohort Study from Vietnam
10135	Che-yu	Hsu	Taiwan	Cytoplasmic Pla2 Contributes to Senescence-Mediated Lipid Accumulation in Primary Human Hepatocytes
10136	Tomoaki	Yoh	Japan	Evolution of Treatment Strategies and the Impact of Major Pathological Response in Borderline Resectable Hepatocellular Carcinoma
10137	Lian-wang	Cai	Taiwan	Extracellular Vesicle Biomarkers Enhance Machine Learning Classification of Obese and Lean Metabolic Dysfunction-Associated Steatotic Liver Disease
10138	Tomoyuki	Satake	Japan	Clinical Outcomes of Cabozantinib During the Ici Era
10139	Bao V	Tran	Japan	Therapeutic Potential of Recombinant Human Cytoglobin in Acetaminophen-Induced Hepatotoxicity: Evidence from in Vivo and Transcriptomic Analyses
10140	Kentaro	Sato	Japan	A Diagnostically Challenging Case of Intrahepatic Cholangiocarcinoma with Surrounding Peribiliary Cysts
10141	Asvin	Selvakumar	Singapore	Comparative Efficacy and Safety of Pharmacological Treatments for Primary Sclerosing Cholangitis: a Systematic Review and Network Meta-Analysis of Randomised Controlled Trials
10142	Inas	Karimi	Indonesia	Hepatorenal Crosstalk in Metabolic Syndrome: Nafld/masld As an Independent Risk Factor for Ckd
10143	Yan	Zhang	China	Akkermansia-Mediated Nutritional Preconditioning Alleviates Cholestatic Liver Fibrosis via the I3a-Ahr-Nrf2 Axis
10144	Rama_maleakhi	Saragih	Indonesia	Differential Associations of Hepatic Steatosis, Metabolic Dysfunction, and Steatohepatitis with Hepatocellular Carcinoma Risk in Chronic Hepatitis B: a Systematic Review and Meta-Analysis
10145	Ruba	Chakma	Thailand	Seroprevalence of Hepatitis E Virus Exposure Among Patients with Hepatocellular Carcinoma in Chiang Mai, Thailand
10146	Firman	Alamsyah	Indonesia	The Effect of Electro-Capacitive Cancer Therapy on Liver Tumor Growth in Mice
10147	Takuya	Seike	Japan	Genetic Masking of Liver Injury: Aldh2*2 Polymorphism Uncouples Serum Alt Levels from Liver Injury in Drinkers

No	First Name	Last Name	Country	Title of Abstract
10148	Taro	Shibuki	Japan	Sex-Based Outcomes of First-Line Systemic Therapy in Advanced Intrahepatic Cholangiocarcinoma
10150	Satoshi	Narahara	Japan	The Harmony Index: an Early Predictor of Primary Resistance to Atezolizumab Plus Bevacizumab in Advanced Hepatocellular Carcinoma
10151	Hery Djagat	Purnomo	Indonesia	Altered Gut Microbial Taxa Are Associated with Metabolically Associated Fatty Liver Disease in Indonesian Adults : a Preliminary Study
10152	Hery Djagat	Purnomo	Indonesia	One in Five Hepatocellular Carcinomas Are Afp-Negative: Clinical Characteristics and Prognostic Implications from Six-Year Indonesian Study
10153	Toshinori	Toyota	Japan	Treatment-Related Skeletal Muscle Loss During Systemic Therapy: a Multicenter Comparison of Atezolizumab Bevacizumab and Lenvatinib in Unresectable Hepatocellular Carcinoma
10154	Seiichi	Mawatari	Japan	Cause-Specific Standardized Mortality Ratios in Patients After HCV Eradication with Direct-Acting Antivirals
10155	Sae Kyung	Joo	Korea	Sex Differences in Fatty Liver Prevalence at Comparable Body Fat Levels: the Contribution of Central Adiposity
10157	Balaussa	Absamat	Kazakhstan	Self-Reported Hepatitis B Vaccination Status and Knowledge, Attitudes, and Practices Towards Hepatitis B Among Medical Students in Kazakhstan: a Cross-Sectional Study
10158	Sae Kyung	Joo	Korea	Sex-Specific Determinants of Fibrosis Progression in Masld: the Role of Menopause and Endogenous Estrogen Exposure
10159	Tzu Ya	Lien	Taiwan	Impact of Initial Surgery on Survival Outcomes in Combined Hepatocellular-Cholangiocellular Carcinoma: a Single-Center Retrospective Analysis
10160	Haruki	Uojima	Japan	Lsm Combined with M2bpgi Improves Exclusion of High-Risk Esophageal Varices Compared with the Baveno 7 Criteria
10161	Kengo	Watanabe	Japan	Differential Impact of Steatotic Liver Disease on Liver Fibrosis Progression According to Hepatitis B Virus DNA Levels in Untreated Patients with Chronic Hepatitis B Virus Infection Patients
10162	Kotaro	Doi	Japan	Longitudinal Increase in FIB-4 Index and Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Receiving Nucleos(t)ide Analogues: a Multicenter Study
10163	Yong Wen	Leow	Singapore	A Meta-Analysis of Pharmacological Treatments for Sarcopenia in Older Adults from Randomized Controlled Trials
10165	Asgar	Ali	India	Pten As a Diagnostic and Prognostic Biomarker in Periampullary Cancer: a Tissue-Based Molecular Study from India
10166	Harshita	Dubey	India	Chemotherapy Induced Hepatic Steatosis in Ovarian Cancer
10167	Soon Kyu	Lee	Korea	Swe Performs Comparably to Vcte in a FIB-4 Based Two-Step Risk Stratification Strategy for MASLD
10168	Tingyu	Lin	Taiwan	Gastrointestinal Bleeding Risk and the Value of Endoscopic Assessment in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab
10169	Sang Gyune	Kim	Korea	Fibrosis Burden Outperforms HBV DNA in Predicting Hepatocellular Carcinoma and Liver-Related Outcomes in Patients with Indeterminate-Phase Chronic Hepatitis B
10170	Sachiyo	Yoshio	Japan	Short-Term Exercise, But Not Bariatric Surgery, Reverses Cd4⁺ T-Cell Exhaustion in Severe Obesity and MASLD
10171	Naoshi	Odagiri	Japan	Association of Serum Full-Length Glypican-3 with Clinical Outcomes in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab and Bevacizumab
10172	Anfal Abdelazeim Abbass	Taifour	Sudan	Hemochromatosis Presenting with Severe Jaundice, Arthralgia, Amenorrhea, and Bronze Skin Pigmentation Mimicking Acute Viral Hepatitis :a Case Report
10173	Hidekazu	Yamamoto	Japan	Clinical Outcomes of Conversion Surgery Following Immune Checkpoint Inhibitor Therapy in Patients with Advanced Hepatocellular Carcinoma
10174	Joji	Tani	Japan	Real-World Outcomes and Treatment Strategy of Durvalumab Plus Tremelimumab in Unresectable Hepatocellular Carcinoma: a Multicenter Study of 448 Patients
10175	Ryosuke	Imado	Japan	Comparison of Therapeutic Efficacy Between Rifaximin and L-Carnitine for Hyperammonemia in Liver Cirrhosis: a Multicenter Retrospective Study Focusing on Long-Term Event Prevention
10176	Takeshi	Matsui	Japan	Clinical Characteristics of Patients with Spontaneous Rupture of Hepatocellular Carcinoma at a Single Center
10177	Satoru	Kakizaki	Japan	The Fib-3 Index Outperforms FIB-4 and Shows Comparable Prognostic Performance to Amap and MELD in Patients with Hepatic Encephalopathy Receiving Rifaximin: a Multicenter Retrospective Analysis
10178	Yoshihiro	Kamada	Japan	Delphi-Based Non-Invasive Algorithms for Liver-Directed Semaglutide Therapy in MASLD
10179	Satoru	Kakizaki	Japan	Long-Term Outcomes of Sofosbuvir/velpatasvir Treatment for Hepatitis C Virus-Related Decompensated Cirrhosis: a Retrospective Multicenter Cohort Study
10180	Maiko	Nagaoka	Japan	Serum Mac-2 Binding Protein Glycosylation Isomer Is Associated with Physical Frailty in Community-Dwelling Older Adults
10181	Aswanth	Ks	India	Impact of Sarcopenia in Early Outcomes of Pediatric Liver Transplantation: a Single-Centre Cohort Study
10182	Takumi	Tanizaki	Japan	Hypersplenism Promotes Liver Fibrosis Through a Tgf-β-Mediated Spleen-Liver Axis: a Murine Study of Splenic Macrophages
10183	Aswanth	Ks	India	Calfan Syndrome: an Unusual Cause of Infantile Acute-On-Chronic Liver Failure
10184	Daiki	Maeda	Japan	Early AFP Reduction Predicts Conversion Therapy and Long-Term Survival in Br2 Hepatocellular Carcinoma
10185	Tanya	Jayakar	United Kingdom	FIB-4 Retains Its Ability to Predict Adverse Clinical Outcomes in MASLD Patients with Normal Alt Levels
10186	Meti	Metiani	Indonesia	Pnpla3 Rs738409 As a Genetic Driver of Mafld in Type 2 Diabetes Mellitus: a Systematic Review and Meta-Analysis
10187	Sota	Nakamura	Japan	Metabolic Refinement of Oncological Resectability Classification Using Fdg-Pet-Derived Suvmax in Resected Hepatocellular Carcinoma
10188	Kazuhito	Kawata	Japan	Awareness of Viral Hepatitis Among Junior and Senior High School Students and the Effectiveness of a School-Based Educational Program: a Large-Scale Longitudinal Study
10189	Tatsuo	Kanda	Japan	Cabozantinib Could Inhibit Hepatitis a Replication in Human Hepatocytes
10190	Ariunzaya	Munkhchuluun	Mongolia	Comparison of Bevacizumab Treatment Outcomes by Hepatitis Virus Infection, Gender, and Age Group
10191	Tatsuo	Kanda	Japan	Acute-On-Chronic Liver Failure Following Pneumonia in an Elderly Woman with Metabolic Dysfunction-Associated Steatotic Liver Cirrhosis
10192	Erdenebayar	Gonchig	Mongolia	Declining Trends of Hepatitis Virus Prevalence in Mongolia: an Analysis Based on Early Detection Data
10195	Harsha Vardhan	Manjunatha	India	Efficacy and Safety of Combining Immune Checkpoint Inhibitors with Transarterial Radioembolization in Advanced/unresectable Hepatocellular Carcinoma: a Systematic Review and Meta-Analysis
10196	Yoji	Ishizu	Japan	Association of Neuropsychological Test Abnormalities, Polypharmacy, and Liver Functional Reserve with Medication Understanding in Patients with Liver Disease
10197	Katsuya	Nagaoka	Japan	Bridging the Surveillance Gap in Steatotic and Alcohol-Related Hepatocellular Carcinoma

No	First Name	Last Name	Country	Title of Abstract
10198	Haruki	Ichino	Japan	Nucleos(t)ide Analogs for Hepatitis B Virus Infection Differentially Regulate the Growth Factor Signaling in Hepatocytes
10199	Hironao	Okubo	Japan	Treatment of Unresectable Hepatocellular Carcinoma with Cabozantinib in the Era of Immunotherapy: Importance of Treatment Sequence
10200	Kazuhiro	Murai	Japan	Identification of HBV Therapeutic Targets Using Primary Human Hepatocytes by Single-Cell RNA Sequencing
10201	Masakuni	Tateyama	Japan	Development of Hepatocellular Carcinoma After the Eradication of Hepatitis C Virus by Direct-Acting Antivirals and Outcome of the Patients with Sustained Virological Response
10202	Takuya	Oba	Japan	Case Series of Robotic Reduced Port Hepatectomy Using Senhance Digital Laparoscopy System
10203	Yasuteru	Kondo	Japan	Partial Splenic Embolization Improves Hepatic Reserve and Nlr, Supporting Multidisciplinary Treatment for Hepatocellular Carcinoma
10204	Tatsunori	Kondo	Japan	A Case of Autoimmune Hepatitis-Primary Biliary Cholangitis Overlap Syndrome Associated with Immune Thrombocytopenia
10205	T	Ishikawa	Japan	Lactylation Regulates Ferroptosis Through Mettl3 in Hepatocellular Carcinoma
10206	Nisrin Binti	Abd Kadir	Malaysia	Pesticide-Induced Oxidative Stress in Rice (<i>oryza Sativa</i> L Cv Mr263): a Possible Link to Hepatotoxic Risk in Consumers
10207	Chi-yu	Lee	Taiwan	Clinical Significance of Durable Response to Immune Checkpoint Inhibitors in Unresectable Hepatocellular Carcinoma
10208	Lingyan	Zhao	China	Mechanism of Mir-10a-5p Delivered by Adipose-Derived Mesenchymal Stem Cell Exosomes in Alleviating Autoimmune Hepatitis via Suppressing Ferroptosis
10209	Hiroteru	Kamimura	Japan	Effects of Voluntary Wheel Running on Hepatic Tissue and Skeletal Muscle in MASH Model Mice and Underlying Mechanisms
10210	Khongorzul	E	Mongolia	Correlation Between Liver Biomarkers and Hemoglobin Levels
10211	Ryoko	Asari	Japan	Early Real-World Experience Integrating Point-Of-Care Hbeag-Hs Rapid Testing Into Routine Antenatal Services for HBV Pmtct in the Gambia
10212	Ryoko	Asari	Japan	Nationwide Integration of Hepatitis B Into Antenatal Care for Triple Elimination of Mother-To-Child Transmission of Hiv, Syphilis, and Hepatitis B in the Gambia: Early Lessons from Global Fund-Supported Scale-Up
10213	Junya	Mita	Japan	Fsp1 Drives Ferroptosis Resistance and an Immunosuppressive Tumor Microenvironment in Hepatocellular Carcinoma
10215	Erdenebayar	Gonchig	Mongolia	Association Between Glycemic Control (HbA1c) and Liver Transaminase Levels (alt and Ast)
10216	Oyunselenge	B	Mongolia	Association of HbA1c with Liver Steatosis and Fibrosis
10217	Amarsanaa	Jazag	Mongolia	A-Hoc Study on Patients Under Surveillance for Liver Cancer in Mongolia
10218	Erdenetsogt	Dungubat	Japan	Automated Quantification of Interlobular Bile Duct Loss in Whole-Slide Liver Images Using Deep Learning in a Mouse Model of Primary Biliary Cholangitis
10219	Tomomi	Kogiso	Japan	Association Between Hepatic Steatosis and Hepatocellular Carcinoma Risk in Patients with Chronic Hepatitis B
10220	Amarsanaa	Jazag	Mongolia	Study on Patients Undergoing Triple Therapy for Liver Steatosis in Mongolia
10221	Yuwa	Ando	Japan	Hepatic Resection Following Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma: a Single-Center Experience and Clinical Implications
10222	Erdenebayar	Gonchig	Mongolia	Age-Specific Prevalence of Viral Hepatitis in Mongolia
10223	Tomoko	Aoki	Japan	Stromal-Rich Tumor Immune Microenvironment in Fdg-Pet-Positive Hepatocellular Carcinoma
10224	Tamami	Abe	Japan	Metabolic Surgery Resolves Liver Fibrosis Independently of Steatosis in MASH: Insights from Laparoscopic Sleeve Gastrectomy
10227	Yu-ching	Huang	Taiwan	Tryptophan Metabolites Attenuates Liver Fibrosis by Modulating Hepatic Stellate Cell Status and Restoring Mitochondrial Dynamics in Masld/MASH
10228	Hirayuki	Enomoto	Japan	Etiological Transitions in Patients with Liver Cirrhosis and HCC-Complicated Cirrhosis: a Single-Center Study from an Institution in a District Area with a High Prevalence of Viral Hepatitis
10229	Hirayuki	Enomoto	Japan	Hepatoma-Derived Growth Factor As a Potential Therapeutic Target for Hepatocellular Carcinoma
10230	Yosuke	Fujii	Japan	Hepatocyte-Specific <i>arid1a</i> Loss Favors Hepatocarcinogenesis Under Chronic Liver Injury
10231	Takao	Shimizu	Japan	Real-World Outcomes of Short-Course Len-Tace Sequential Therapy for Intermediate-Stage Hepatocellular Carcinoma
10232	Hiroko	Setoyama	Japan	Clinical Significance of Hepatocellular Carcinoma Risk Stratification in Patients with Chronic Hepatitis B in the Indeterminate Phase
10233	Kotaro	Kumagai	Japan	Gpnmb Drives Macrophage-Mediated Immune Suppression and T Cell Dysfunction in Hepatocellular Carcinoma
10234	Miuzki	Endo	Japan	Long-Term Investigation of Hepatocarcinogenesis in Patients with Type 2 Diabetes Mellitus: a 20-Year Prospective Cohort Study
10236	Haruna	Noguchi	Japan	Prime Editing Enables Isogenic Modeling of Pnpla3-I148m-Associated Lipotoxicity in Hepatocytes
10237	Song Huy	Nguyen Dinh	Viet Nam	Hepatocellular Carcinoma (HCC): Challenges in Screening, Diagnosis, and Management in Vietnam
10238	Song Huy	Nguyen Dinh	Viet Nam	Liver Resection for HCC with Portal Vein Tumor Thrombosis (pvtt): Current Challenges and Long-Term Outcomes
10239	Song Huy	Nguyen Dinh	Viet Nam	Long-Term Outcomes and Prognostic Factors Following Liver Resection for Hepatocellular Carcinoma
10240	Masahito	Nakano	Japan	Nationwide Trends in Liver Stiffness Measurement in Japan: Real-World Evidence from the National Database of Health Insurance Claims
10242	Tsubasa	Tsutsumi	Japan	Triglyceride-To-Hdl Cholesterol Ratio Identifies Coronary-Predominant Cardiovascular Risk in Patients with MASLD
10244	Tatia	Khachidze	Georgia	A Narrative Review of the Diagnostic Performance of Non-Invasive Scoresfor Predicting Fibrosis in MaflD
10245	Tatia	Khachidze	Georgia	The Role of Probiotics and Prebiotics in the Management of Masld: Aclinical Perspective
10246	Hiroaki	Matsumoto	Japan	Early Real-World Experience with Nivolumab Plus Ipilimumab for Unresectable Hepatocellular Carcinoma: a Single-Center Experience in Japan
10247	Tsubasa	Tsutsumi	Japan	Low Muscle Mass Across Ckm Stages: Cross-Population Mediation, Mortality, and Multi-Omics Evidence
10248	Tanusree Saha	Mumu	British Indian Ocean Territory	Hepatic Amyloidosis Presenting As Cholestatic Liver Disease with Portal Hypertension: a Case Report

No	First Name	Last Name	Country	Title of Abstract
10249	Tsubasa	Tsutsumi	Japan	Sarcopenic Obesity Is Associated with MASLD and All-Cause Mortality Among Adults with Obesity
10250	Nobuyo	Higashi-kuwata	Japan	<i>in Vitro</i> Anti-HBV Activity of a Novel Nucleoside Analog <i>e</i>-Cfcp Combined with an HBV-Rna-Targeting Agent Bepirovirsen
10251	Xian-yang	Qin	Japan	Mycn Defines Stress-Adaptive Cell States in Hepatocellular Carcinoma
10252	Tomoko	Koda	Japan	Preliminary Analysis of Hepatic Pgc-1a Expression Following Melatonin Administration in an Adenine-Induced Chronic Kidney Disease Mouse Model
10253	Kyoko	Oura	Japan	Clinical Impact of Sarcopenia Diagnosed Using Handgrip Strength and Skeletal Muscle Index in Patients with Hepatocellular Carcinoma Receiving Combination Immunotherapy
10254	Takemi	Akahane	Japan	Serum Cytokeratin-18 Fragment Refines FIB-4 Index–based Risk Stratification for At-Risk MASH
10255	Shuntaro	Obi	Japan	Adding Afp-L3 and Dcp to AFP Enables Detection Very Small HCC: Validation with A-Hoc Study
10256	Shuntaro	Obi	Japan	Galad Maintains a High Positive-Range Classification Rate Across HCC Etiologies Despite Differences in Tumor Burden: Validation in the A-Hoc Study
10257	Chang-chieng	Soon	Taiwan	Immune-Mediated Clopidogrel-Induced Drug-Induced Liver Injury Confirmed by Drug-Specific Lymphocyte Transformation Test: a Case Report and Literature Review
10258	Shinya	Hayami	Japan	Perioperative Detection of Second Primary Malignancies in Patients Undergoing Hepatectomy for Hepatocellular Carcinoma
10259	Masashi	Nakamura	Japan	Smyd2 Regulates Lymph Node Metastasis Derived from Intrahepatic Cholangiocellular Carcinoma Through Ccr7-Dependent Chemotaxis
10260	Ryotaro	Sakamori	Japan	Clinical Event Risk in Patients with Masld: Findings from a Prospective Multicenter Registry
10261	Riku	Nakashima	Japan	Clinical Outcomes of Durvalumab Plus Tremelimumab Therapy for Advanced Hepatocellular Carcinoma: a Single-Center Retrospective Study
10262	Xin	Zheng	Japan	Identification of Novel Antiviral Agent Against Hepatitis a Virus Replication
10263	T	Oga	Japan	A Case of a Rapidly Growing Inflammatory Hepatocellular Adenoma Treated with Robot-Assisted Liver Resection
10264	Naoto	Izumi	Japan	Long-Term Outcomes After Subsequent Anticancer Treatment for Ruptured Hepatocellular Carcinoma
10265	Vinh_h	Vu	Viet Nam	Worse Long-Term Clinical Outcome After Hepatitis C Cure Among People Who Inject Drugs Living with Hiv in Vietnam
10266	Shunhei	YaMASHina	Japan	Cathepsin L Inhibitor Enhances Liver Regeneration in Fibrotic Liver
10267	Duong Thuy	Phung	Viet Nam	Stereotactic Body Radiotherapy (sbrt) Achieves Lasting Response After Sequential Tace and Multiline Systemic Therapy Failure in Intermediate-Stage Hepatocellular Carcinoma: a Case Report
10268	Keiichi	Katayama	Japan	Impact of Acid-Suppressing Therapy on Hepatic Encephalopathy and Spontaneous Bacterial Peritonitis in Patients with Liver Cirrhosis: a Prospective Cohort Study
10269	Misaki	Matsui	Japan	Radiotherapy (rt) for Hepatocellular Carcinoma at Our Institution
10270	Chikako	Sakai	Japan	Real-World Efficacy and Safety of Tirzepatide in Patients with T2dm and Masld: a Prospective Cohort with Multicenter Retrospective Validation
10271	Koji	Fujita	Japan	Investigation of Metabolic Pathways Associated with Sensitivity to Multikinase Inhibitors in Hepatocellular Carcinoma
10272	Hiroumi	Akita	Japan	Factors Associated with Long-Term Survival in Intrahepatic Cholangiocarcinoma: a Single-Center Real-World Analysis
10275	Wenzhen	Ding	China	A Multimodal Highly Conformal Ablation Planning System for Hepatocellular Carcinoma: a Multicenter Retrospective and Prospective Study
10276	Doaa A	Abo Elwafa	Japan	Enhanced Suppression of Hepatitis D Virus Infection by a Newly Developed Rxr Agonist Targeting Ntcp Mediated Viral Entry
10277	Abdulla A	Mahmoud	Japan	Cathepsin F Supports HBV/hdv Entry Into Human Hepatocytes and Represents a Promising Antiviral Target
10278	Yoshinari	Asaoka	Japan	Efficacy and Severe Iraes of First-Line Nivolumab Plus Ipilimumab for Advanced Hepatocellular Carcinoma: a Case Series
10279	Tri	Hartanto	Indonesia	Occult Satellite Lesions in Low-Afp Hepatocellular Carcinoma: Implications of Afp-Negative Phenotypes in Early-Stage Disease
10280	Agus	Sukamto	Indonesia	From Presumed Hepatocellular Carcinoma to Intrahepatic Cholangiocarcinoma: the Impact of Tissue Diagnosis on Clinical Management and Treatment Outcome
10281	Esraa	Kamal	Japan	High Throughput Identification of a Potent Inhibitor of Hepatitis B Virus Infection
10282	Kazuya	Minamoto	Japan	A Case of Pet-Negative Intrahepatic Cholangiocarcinoma That Was Difficult to Diagnose
10283	Kenta	Suzuki	Japan	Long-Term Outcomes in Patients with Decompensated Cirrhosis Who Achieved Svr: a Multicenter Study
10284	Yutaka	Yasui	Japan	Comprehensive Genomic Profiling in Advanced Hepatocellular Carcinoma: Real-World Cohort
10285	Akemi	Tsutsui	Japan	Clinicopathological Factors Associated with Relapse During Prednisolone Therapy in Acute-Onset Autoimmune Hepatitis
10286	Mitsuki	Ishida	Japan	Methotrexate-Induced Portosinusoidal Vascular Disorder Presenting with Splenomegaly and Periumbilical Varices in a Rheumatoid Arthritis Patient: Confirmation by Drug-Induced Lymphocyte Stimulation Test
10287	Kazunari	Tanaka	Japan	Clinical Impact of Beta-D-Glucan Positivity in Patients with Acute Liver Failure
10288	Yuki	Kugiyama	Japan	Incidence, Risk Factors, and Prognosis of Hepatocellular Carcinoma in Patients with Primary Biliary Cholangitis: a Nationwide Japanese Cohort Study
10289	Yuki	Motokawa	Japan	Vwf/adamts13 Ratio Improves the Diagnosis of Sarcopenia in Patients with Liver Cirrhosis
10290	Yi-hsuan	Li	Taiwan	Exercise-Induced Changes in Serum Extracellular Vesicle-Associated Oxidative Status in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease
10291	Asahiro	Morishita	Japan	PD-L1 Gene Polymorphisms As Predictive Biomarkers for Immune Checkpoint Inhibitor Combination Therapy in Unresectable Hepatocellular Carcinoma
10292	Hiroyuki	Kobayashi	Japan	Community-Based Hepatitis B Virus Screening Identifies Previously Undiagnosed Patients Requiring Antiviral Therapy in a Rural Japanese Population: the Nagawa Project
10293	Junichi	Hanatani	Japan	Efficacy and Safety of Nalmefene on Alcohol Consumption, Liver Function, and Gut Microbiota in Alcohol-Related Liver Disease
10294	Masaru	Muraoka	Japan	a Study Using Mre and Neuropsychological Test Subtests for Stratification of Minimal Hepatic Encephalopathy Risk
10295	Marco	Distefano	Italy	Claire: a Zero-Code, Uncertainty-Aware Llm Agent Transforming Cirrhosis Records Into Actionable Intelligence for Liver Cancer Control

No	First Name	Last Name	Country	Title of Abstract
10296	Jui-chi	Yu	Taiwan	Poly(ethylene Glycol)-Block-Poly(cysteine) Block Copolymer-Based Self-Assembling Nanoparticles Attenuate Oxidative Stress in Primary Human Hepatocytes
10297	Taeang	Arai	Japan	Optimizing Fib-4-Based Stepwise Risk Stratification in Masld: Reducing Missed Advanced Fibrosis in Type 2 Diabetes
10298	Sho	Ijuin	Japan	Prognostic Impact of Nutritional Assessment Markers in Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab
10299	Michitaka	Matsuda	Japan	Intratumor Immunofibrosis Profile Associated with Hepatocellular Carcinoma Recurrence
10300	Takehisa	Watanabe	Japan	Advancing Sag-524, an Oral Papd5-Targeting Small Molecule, Toward First-In-Human Clinical Development for Functional Cure of Chronic Hepatitis B
10301	Takako	Inoue	Japan	Improving Medical Attendance Confirmation for Hepatitis Testing-Positive Individuals: a Seven-Year Study in Aichi, Japan
10302	Yuki	Minetoma	Japan	Durable Drug-Free Complete Response to Atezolizumab Plus Bevacizumab in Advanced Hepatocellular Carcinoma with Major Portal Vein Invasion After Managing Portal Hypertension: a Case-Based Cohort Analysis
10304	Ha H	Pham	Viet Nam	Greyzone in Treatment-Naïl;ve Chronic Hepatitis B Patients: Prevalence and Clinical Characteristics in a Referral Hospital in Vietnam
10305	Akio	Moriya	Japan	Factors Associated with Alanine Aminotransferase Improvement After Initiation of Tirzepatide in Patients with Type 2 Diabetes
10306	Yuji	Ikeda	Japan	Identifying Significant Fibrosis in Health-Check Masld: Added Value of Maf-5 in Normal Alt and Non-Obese Individuals
10307	Zento	Yamada	Japan	Prognostic Value of an Early Response to Tolvaptan and Its Clinical Implications in Patients with Cirrhosis and Hepatic Edema
10308	Fatimah	Abd Kadir	Malaysia	Photocatalytic Degradation of Methylene Blue to Mitigate Liver Disease: a Step Toward Sustainable Wastewater Treatment
10309	Takanori	Ito	Japan	Risk Factors and Prognostic Impact of Severe Immune-Mediated Hepatotoxicity in Patients with Unresectable Hepatocellular Carcinoma Treated with Durvalumab Plus Tremelimumab
10310	Keisuke	Koroki	Japan	Comparative Analysis of Immune-Mediated Adverse Events and Early Efficacy of Durvalumab + Tremelimumab and Nivolumab + Ipilimumab in Advanced Hepatocellular Carcinoma
10311	Jinlin	Hou	China	Clinically Meaningful Rates of Functional Cure and Hepatitis B Surface Antigen Reduction in Patients with Virologically Suppressed Chronic Hepatitis B Virus Infection Treated with Bepirovirsen: B-Well Phase 3 Trials
10312	Chikara	Ogawa	Japan	Real-World Efficacy and Safety of Avatrombopag for Thrombocytopenia in Chronic Liver Disease Patients Undergoing Invasive Procedures
10313	Yasuhide	Motoyoshi	Japan	Two Cases of Cytokine Release Syndrome (crs) During Combination Immunotherapy for Unresectable Hepatocellular Carcinoma
10314	Jun	Arai	Japan	Efficacy of Scheduled Lenvatinib Plus Tace for Intermediate-Stage, Tace-Unsuitable Hepatocellular Carcinoma
10315	Makoto	Fujiya	Japan	Integrated Histologic and Imaging Features Define Morphologic Clusters Associated with Tumor Microenvironment Profiles in Advanced Hepatocellular Carcinoma
10316	Yutaro	Hori	Japan	Verification of the Therapeutic Effect of Dual Immune Checkpoint Inhibitor for Advanced Hepatocellular Carcinoma Using Previously Reported Treatment Effect Predictors
10317	Takashi	Honda	Japan	Association Between Hepatitis B Virus Mutation Rates and Clinical Outcomes in Chronic Hepatitis B
10318	Shah_emptiaz	Rahman	Bangladesh	Spleen Stiffness Outperforms Conventional Fibrosis Markers for Predicting Esophageal Varices in Cirrhosis
10319	Sourav_kumar	Chakraborty	Bangladesh	Tace Plus Lenvatinib Improves Objective Response and Downstaging Within Ucsf Criteria in Treatment-Naive Unresectable HCC: a Comparative Study
10320	Shohei	Shiota	Japan	Characteristics of Ruptured Liver Cancer Cases Experienced Over the Past Year
10321	Masaaki	Hidaka	Japan	Liver Resection Following Multidisciplinary Treatment for Borderline Resectable Hepatocellular Carcinoma (br2): a Report of Four Cases
10322	Akihiro	Deguchi	Japan	Clinical Impact of Incorporating New Fp Hepatic Arterial Infusion Chemotherapy Into the Sequential Treatment Strategy After Combination Immunotherapy for Unresectable Hepatocellular Carcinoma
10323	Ariunaa	Baljinnyam	Mongolia	The Effect of Semaglutide on Weight Loss and Liver Fat Reduction in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (masld)
10324	Li-wen	Lin	Taiwan	Soat-Mediated Cholesterol Esterification Safeguards Against Hepatocyte Senescence and Inflammatory Sasp Activation
10326	Ryuki	Hashida	Japan	Safety and Feasibility of Supervised Low-Intensity Rehabilitation in Decompensated Liver Cirrhosis
10327	Xiang	Zhou	Japan	Twenty-Year Trends in Liver Biopsy Practice: from Viral Hepatitis to Steatotic Liver Disease and Autoimmune Liver Diseases
10328	Minkyung	Gu	Korea	Ai-Based Integrative Analysis of Alcohol Associated Liver Injury
10329	Tomotake	Shirono	Japan	Treatment Outcomes and Prognostic Analysis in Unresectable Intrahepatic Cholangiocarcinoma: a Multicenter Retrospective Study Using Real-World Data
10330	Jumpei	Okamura	Japan	Impact of Alcohol Intake on the Efficacy of a Moderate-Carbohydrate Diet in Patients with MASLD
10331	Tomoaki	Emori	Japan	Efficacy, Safety, and Genomic Profiling of Gcd/gcp Therapy for Unresectable Intrahepatic Cholangiocarcinoma: a Real-World Study
10332	Daigo	Mamitsuka	Japan	Clinical Outcomes of Durvalumab Plus Tremelimumab for Advanced Hepatocellular Carcinoma: a Case Series Highlighting an Exceptional Response in Concomitant Mss Colorectal Cancer
10334	Hyunjin	Jeong	Korea	Loss of Erdj5 Drives Sorafenib Resistance in Hepatocellular Carcinoma by Regulating Gpx4-Dependent Ferroptosis
10335	Ankita	Chatterjee	India	Single-Nucleus Sequencing Reveals the Oncogenic Rewiring of Ballooned Hepatocytes in MASLD
10336	Mitsuki	Ishida	Japan	Porto-Sinusoidal Vascular Disorder as a Cause of Non-Cirrhotic Portal Hypertension in a Patient with Rheumatoid Arthritis on Long-Term Methotrexate and Iguratimod
10337	Tatsuo	Kanda	Japan	Pemafibrate Effectively Prevented Liver Dysfunction in Young Female with Anorexia Nervosa
10338	Makoto	Chuma	Japan	Clinical Significance of Circulating Biomarkers of Immune Checkpoint Molecules with Atezolizumab Plus Bevacizumab Therapy in Unresectable Hepatocellular Carcinoma
10339	Naoki	Yamamoto	Japan	Development of a Highly Sensitive Rapid Test for the Detection of Hepatitis B Core-Related Antigen
10340	Mohammad Ahmadullah	Khan	India	FIB-4 False Negatives in Masld: Clinical Phenotypes and an Augmented Triage Mode
10341	Taotao	Yan	China	Antiviral Therapies Are Under-Utilized in Patients with Hepatitis B-Related Hepatocellular Carcinoma Despite Substantial Survival Benefits
10342	Makiko	Taniai	Japan	Clinical Aspects of Hepatocellular Carcinoma in Autoimmune Liver Diseases
10343	Chia-yang	Li	Taiwan	Genomic Signatures Associated with Different Stages of Fibrosis in MASLD and Semaglutide Treatment Effects

No	First Name	Last Name	Country	Title of Abstract
10344	Rui	Huang	China	Ireal-B As a Simple Risk Score for Predicting Hepatocellular Carcinoma in Untreated Indeterminate Chronic Hepatitis B Patients
10345	Natsuko	Nishiyama	Japan	Evaluation of Portal Venous Hemodynamics in Portal Hypertension Using MRI
10346	Kenta	Yamamoto	Japan	Gut Microbiota-Enhanced Survival Stratification in Hypervascular Hepatocellular Carcinoma
10347	Adinda	Amalia	Indonesia	Beyond Baveno Vii Non-Invasive Criteria: Eus-Ppg Confirmed Clinically Significant Portal Hypertension in MASLD with Low Liver Stiffness
10348	Hung Chih	Chiu	Taiwan	Real-World Outcomes of First-Line Stride for Unresectable HCC
10349	Shinji	Itoh	Japan	Effect of Curative Resection After Atezolizumab Plus Bevacizumab on Outcome in Hepatocellular Carcinoma
10350	Erdenebayar	Gonchig	Mongolia	Patterns of Extrahepatic Metastasis in Hepatocellular Carcinoma
10351	Wu	Chang	Japan	Hepatocyte-Specific Flcn Deficiency Attenuates MASH-Associated Hepatocarcinogenesis
10352	Erdenebayar	Gonchig	Mongolia	Patterns of Liver Metastasis from Extrahepatic Primary Malignancies
10353	Wan-chieh	Li	Taiwan	Cross-Platform Transcriptomic Mapping for Conserved Molecular Axes of Disease Progression in Metabolic Dysfunction-Associated Steatotic Liver Disease
10354	Seong Hee	Kang	Korea	Predictors of Hepatocellular Carcinoma in Cirrhotic Patients: the Role of Glucose Tolerance and Fasting Glycemia
10355	Seong Hee	Kang	Korea	Protective Effect of Sglt2 Inhibitors Against Hepatocellular Carcinoma and Cirrhosis in Patients with Diabetes and Chronic Hepatitis B/c
10356	Hirotooshi	Ebinuma	Japan	A Case of HCC Presenting with Gastric Ulcers by VEGF Inhibition
10357	Cosmas Rinaldi Adithya	Lesmana	Indonesia	The Hidden Portal Pressure Burden in Masld: Eus-Ppg Reveals a Non-Invasive Marker and Portal Pressure Mismatch in a Prospective Pilot Cohort
10358	Pisit	Tangkijvanich	Kingdom of Thailand	Long-Term Effects of HCV Eradication on Steatosis Progression Assessed by Mri-Based Methods: the Role of Gut Microbiota and Systemic Inflammation
10359	Dan	Nakano	Japan	An Association of Covert Hepatic Encephalopathy with Non-Elderly and MASLD in Patients with Liver Cirrhosis and Hepatocellular Carcinoma: Data-Mining Analyses
10360	Jie	Wang	USA	Impact of Metabolic Disease Management on the Survival in Overall, HBV-Related, and Hcv-Related Hepatocellular Carcinoma: a Real-World Cohort Study
10361	Joengin	Lee	Korea	Risk of Mental, Behavioral, and Neurodevelopmental Disorders in Offspring Associated with Maternal Liver Cancer Before Pregnancy
10362	Zhaoyu	Yan	Japan	Rbp3 Is a Novel Host Regulator of HBV Protein Expression and Viral Replication
10363	Keisuke	Ishigami	Japan	Igm-Positive Plasma Cell Tubulointerstitial Nephritis in Patients Diagnosed with Autoimmune Hepatitis and Elevated Serum Igm Levels
10364	Zannatul	Habiba	Bangladesh	Beyond Routine Blood Counts: Neutrophil-To-Lymphocyte Ratio As a Simple Predictor of Liver Cirrhosis Severity a Cross-Sectional Study from Bangladesh
10365	Tadashi	Namisaki	Japan	Impact of the Number of Remaining Natural Teeth on Decompensation and Survival in Patients with Compensated Liver Cirrhosis
10366	Takashi	Nishimura	Japan	Prediction of Hepatocellular Carcinoma Development in Patients with Alcohol-Related Liver Disease Using the Fib-3 Index, FIB-4 Index, and Vibration-Controlled Transient Elastography
10367	Pardeep	Kumar	India	Diagnostic Relevance of Neutrophil Gelatinase-Associated Lipocalin in Cholangiocarcinoma and Biliary Tract Cancers Among Elderly Patients
10368	Pardeep	Kumar	India	Agricultural Exposure to Organic Fungicides and Herbicides and the Risk of Cholangiocarcinoma in Rural Agricultural Workers
10369	Pardeep	Kumar	India	Machine Learning Based Analysis of Epigenetic Signatures in Pediatric Malnutrition: Histone Modification Patterns Associated with Liver Dysfunction and Growth Outcomes
10370	Vikas	Sharma	India	Smartcare-Lc: an Ai Driven Digital Ecosystem for Personalized Precision Oncology in Liver Cancer
10371	Yoshie	Kadota	Japan	Radiofrequency Ablation for Suspected Hepatocellular Carcinoma in a Patient with Hepatitis C-Related Cirrhosis and Situs Viscerum Inversus After the Fontan Procedure: a Case Report
10372	Vikas	Sharma	India	Telemedicine Based Supportive Oncology for Managing Sleep Disturbance and Anxiety in Pediatric Liver Cancer
10373	Ankush	Kumar	India	Central Obesity, Insulin Resistance, and Ldl Cholesterol in Middle-Aged Women with Nonalcoholic Fatty Liver Disease: Implications for Progression to Advanced Liver Disease
10374	Haruhiko	Takeda	Japan	Clinical Utility and Limitations of Comprehensive Genomic Profiling in Immunotherapy-Treated Advanced Hepatocellular Carcinoma: Insights from Multi-Omics Analysis
10375	Ngoc Minh	Nguyen	Viet Nam	Hepatitis B Prevention Knowledge and Attitudes Among Medical Students in Low- and Middle-Income Countries: a Systematic Review
10377	Sotaro	Kurano	Japan	Spatial Transcriptomic Identification of an Inflammatory Tumor Microenvironment in Hbsag Transgenicmice with Diet-Induced MASH
10378	Takahiro	Nishio	Japan	Therapeutic Contorol of Masld-Related HCC